Related Experiment Videos
Thrombolysis in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Insights
Cardiogenic shock following acute myocardial infarction has a high mortality rate, despite advances in care. Early reperfusion therapy shows limited benefit for mortality in these patients.
Area of Science:
- Cardiology
- Critical Care Medicine
Background:
- Cardiogenic shock (CS) following acute myocardial infarction (AMI) carries a high mortality rate, a fact recognized since 1967.
- Despite advancements in cardiovascular care, CS remains the leading cause of death in hospitalized AMI patients.
Purpose of the Study:
- To review the impact of CS in AMI and evaluate the effectiveness of current and potential therapeutic interventions.
- To assess the role of reperfusion therapy, including thrombolytic therapy and percutaneous coronary intervention, in managing CS complicating AMI.
Main Methods:
- Review of historical data and contemporary studies on cardiogenic shock in acute myocardial infarction.
- Analysis of outcomes associated with thrombolytic therapy, reperfusion rates, and adjunctive therapies like intra-aortic balloon pump (IABP).
Main Results:
- Thrombolytic therapy does not decrease mortality in patients with CS at the time of administration but may reduce CS development.
- Reperfusion rates with thrombolysis are lower in CS patients (42-48%) compared to non-CS patients.
- The long-term benefit of IABP and the mortality impact of angioplasty or coronary artery bypass graft (CABG) in CS patients remain undetermined.
Conclusions:
- Cardiogenic shock remains a critical complication of acute myocardial infarction with persistently high mortality.
- Reperfusion strategies, including thrombolysis, have limited direct mortality benefit in established CS, though they may prevent its onset.
- Further research is needed to determine the efficacy of interventions like angioplasty and CABG in improving outcomes for patients with cardiogenic shock complicating AMI.
Abstract:
The adverse impact of the development of cardiogenic shock in the setting of acute myocardial infarction was first described by Killip and Kimball in 1967. While the in-hospital mortality rate in patients with myocardial infarction and no evidence of heart failure was only 6%, the mortality rate in those patients who developed cardiogenic shock was 81%. Despite advances in cardiovascular care and therapy since that initial report, including universal institution of cardiac care units, advances in hemodynamic monitoring, new inotropic and vasodilating agents, and even increasing utilization of thrombolytic therapy, the mortality from acute myocardial infarction, when complicated by cardiogenic shock, remains disturbingly high, and cardiogenic shock remains the leading cause of death of hospitalized patients following acute myocardial infarction.The grave prognosis associated with this condition has resulted in increased interest in potential therapeutic interventions, particularly in the area of reperfusion therapy. Several studies suggest that, in contrast to the beneficial effects of thrombolytic therapy in most patient populations suffering acute myocardial infarction, mortality rates are not decreased in those patients with cardiogenic shock at the time of lytic administration. Thrombolytic administration does, however, appear to lead to a modest reduction in the percent of patients with myocardial infarction who will subsequently develop cardiogenic shock during hospitalization.Reperfusion rates with lytic therapy in patients with cardiogenic shock are disappointingly low, in the range of 42-48%, significantly lower than those achieved in patients without cardiogenic shock. These low perfusion rates may, in part, be explained by decreased coronary blood flow and perfusion pressure in patients with left ventricular pump failure.Although promising as adjunctive therapy, it is unclear whether institution of balloon counterpulsation has any long-term benefit in patients with cardiogenic shock treated with thrombolytic therapy. Whether other or additional interventions, such as coronary angioplasty and coronary artery bypass graft (CABG), decrease mortality rates in patients with cardiogenic shock remains to be determined.